Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational program is directed toward medical oncologists, pathologists, surgical oncologists, and other physicians involved in managing pancreatic cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of molecular profiling to identify actionable alterations in patients with advanced pancreatic ductal adenocarcinoma (PDAC)
- Analyze clinical data from key trials evaluating emerging therapeutic agents for metastatic PDAC
- Integrate recent evidence and current guidelines to develop personalized treatment plans for patients with metastatic PDAC
- Apply strategies to manage treatment-related toxicities in patients with PDAC
Eileen M. O’Reilly, MD
Professor of Medicine
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers Gastrointestinal Oncology Service
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional Research Support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.
E. Gabriela Chiorean, MD, FASCO
Professor of Medicine, Division of Hematology-Oncology
University of Washington
Medical Director, GI Oncology Program
Clinical Research Director, GI Oncology Program
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Advisor: AADi, BMS, BPGbio, Merus, Pfizer, Purple, Regeneron, Takeda; Research: AffiniT, BioAtla, BMS, Erasca, Genentech, Gilead, Lonza, Roche.
Michael J. Pishvaian, MD, PhD
Associate Professor of Oncology
Director of Gastrointestinal, Developmental Therapeutics and Clinical Research
Programs
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Ad Hoc Advisory: AstraZeneca, Merck, Merus, Moderna, Revolution Medicines, Serna Bio; Funding (paid to institution): Actuate, Amgen, Arcus Bio, Astellas, Boehringer, Ingelheim, Elevation Oncology, Ideaya, Lilly, MEI Pharma, Merck, Novartis, Parabalis, Pfizer, Repare Tx, Recursion Pharma, Tesaro; Shareholder: Perthera; Steering committee: Astellas, Merck, RenovoRx; Travel: Merus, RenovoRx, Revolution Medicines.
Brian Wolpin, MD, MPH
Professor of Medicine
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Robert T. & Judith B. Hale Chair in Pancreatic Cancer
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consulting/Advisory Board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Revolution Medicines.
Physicians’ Education Resource® is proud to partner with GI Cancers Alliance
